News Summary: Fast-growing salmon in FDA limbo
December 4, 2012 @ 2:36 pm
(AP) - STAYING AFLOAT: A Massachusetts biotech firm that was poised to become the first company to sell a genetically-modified fish says it may run out of money before regulators approve its fast-growing salmon.
FRANKENFISH: Aquabounty's Atlantic salmon contains an extra hormone that makes it to grow twice as fast as a traditional salmon. Despite concerns from environmentalists, regulators said in 2010 that the fish appeared safe to eat.
RUNNING ON EMPTY: The Food and Drug Administration says it is still working to complete its review of Aquabounty's salmon. Company executives say they only have enough money to operate the company until January.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Top Stories
-

There's a Zone for That
Mapping out a plan for marijuana growers and sellers -

Heartstopping
Daredevils post breathtaking pictures atop Seattle landmarks -

The Wolfpack is Back
Will 'Part III' leave you with a hangover? Find out if it's worth your time
MyNorthwest.com - Purpose of Comments statement
Bonneville Media encourages site users to express their opinions by posting comments. Our goal is to maintain a civil dialogue in which readers feel comfortable. At times, the comments can descend to personal attacks. Please do not engage in such behavior. We encourage your thoughtful comments which: have a positive and constructive tone, are on topic, are respectful toward others and their opinions. Bonneville reserves the right to remove comments which do not conform to these criteria.
Bonneville Media encourages site users to express their opinions by posting comments. Our goal is to maintain a civil dialogue in which readers feel comfortable. At times, the comments can descend to personal attacks. Please do not engage in such behavior. We encourage your thoughtful comments which: have a positive and constructive tone, are on topic, are respectful toward others and their opinions. Bonneville reserves the right to remove comments which do not conform to these criteria.








